Advanced Therapy Medicinal Products Market report categorizes the report by Product, Diseases, End User and geography. It provides information about - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Seattle, WA -- (SBWire) -- 10/01/2019 --Advanced Therapy Medicinal Products (ATMPs) contain cell therapy, gene therapy, and tissue engineered products. Cell therapy products include cellular immunotherapies and autologous and allogeneic cells for certain therapeutic indications such as adult and embryonic stem cells. Human gene therapy includes products that induce genetic material into individuals DNA in order to treat a disease or abnormal medical condition by replacing faulty or missing genetic material. ATMPs can be a boon for the treatment of diseases that have currently limited or no therapeutic options such as hemophilia, cystic fibrosis, metabolic disorders, muscular dystrophies, skin burns, Alzheimer's disease, and cancer. ATMPs are an emerging technology and are in an early stage of development. The approach has potential to cure chronic conditions than standard treatments, which is expected to increase adoption of ATMPs in the near future. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regulate and authorize marketing of ATMPs in the U.S. and Europe, respectively.

Get Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1101

Increasing prevalence of Alzheimer's disease is expected to boost growth of the advanced therapy medicinal products market

Increasing prevalence of Alzheimer's disease is expected to drive growth of the advanced therapy medicinal products market. For instance, according to Alzheimer's Disease International, in 2017, around 50 million people were estimated to suffer from Alzheimer's disease across the globe. Moreover, increasing demand for gene therapies used in the treatment of ocular, neurodegenerative diseases, and several cancers and technological advancements in genetic engineering tools such as RNAi  is also expected to propel growth of the advanced therapy medicinal products market.

However, inadequate transparency and lack of investments and regulatory guidance for biopharmaceutical companies to manufacture these therapies and products is expected to hamper growth of the advanced medicinal therapy products market.

Advanced Therapy Medicinal Products Market Taxonomy:

Advanced therapy medicinal products are segmented on the basis of therapy, diseases, and geography

On the basis of products, the global advanced therapy medicinal products market are segmented into:
- Somatic Cell Therapy Medicinal Products
- Tissue Engineered Medicinal Products
- Gene Therapy Medicinal Products

On the basis of diseases, the global advanced therapy medicinal products market are segmented into:
- Alzheimer's
- Cystic Fibrosis
- Muscular Dystrophies
- Hemophilia

On the basis of region, the global advanced medicinal therapy products market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global advanced medicinal therapy products market. This is attributed to significant advancements in the field of cell and gene therapy. For instance, the innovative gene therapy known as CAR-T or chimeric antigen receptor T-cell therapy harnesses the body's own immune cells to recognize and attack malignant cells. The T-cells are harvested and modified with a new gene. The new gene contains a protein that directs the T-cells to target and kill leukemia cells that have a specific antigen on the surface.

For More Details, Click @ https://www.coherentmarketinsights.com/ongoing-insight/advanced-therapy-medicinal-products-market-1101

Moreover, increasing approval of new therapies is also expected to boost the market growth. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved first gene therapy in the U.S. for the treatment of cancer and other serious and life-threatening diseases.  Moreover, in 2017, the U.S. FDA approved Kymriah, a cell based gene therapy in the U.S. for the treatment of patients with a form of acute lymphoblastic leukemia. Such developments are expected to boost growth of the market in North America. The market in Asia Pacific is expected to witness the fastest growth, owing to increasing cases of skin burns and cancer.

Major players in the market are focused on adopting merger and acquisition strategies to expand their product portfolio. For instance, Pfizer acquired Bamboo Therapeutics, a biotechnology company focused on developing gene therapies for the treatment of patients with diseases related to neuromuscular conditions and the diseases affecting central nervous system. The acquisition is expected to significantly expand Pfizer's expertise in gene therapy by providing clinical and pre-clinical assets to balance the rare disease portfolio of company with advanced recombinant Adeno Associated Virus vector design and production technology, which is fully functional phase I/II gene therapy with manufacturing facilities.

Key players operating the advanced therapy medicinal products market include, Uniqure, Pfizer, Bluebird Bio Inc., BioMarin Pharmaceutical, Novartis AG, GE Healthcare, Shire Biotechnology, and Kite Pharma.

Order a Copy of Global Advanced Therapy Medicinal Products Market Report 2018 @ https://www.coherentmarketinsights.com/insight/buy-now/1101

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.